4/14
08:42 am
hoth
Rewriting Fat Itself: Hoth Therapeutics May Be Targeting the Root of Metabolic Disease [TheStreet.com]
Medium
Report
Rewriting Fat Itself: Hoth Therapeutics May Be Targeting the Root of Metabolic Disease [TheStreet.com]
4/14
07:00 am
hoth
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
High
Report
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
4/13
06:32 pm
hoth
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide [Yahoo! Finance]
High
Report
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide [Yahoo! Finance]
4/13
05:38 pm
hoth
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide [TheStreet.com]
Medium
Report
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide [TheStreet.com]
4/13
05:23 pm
hoth
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
High
Report
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
4/2
04:05 pm
hoth
Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
Medium
Report
Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
4/1
02:20 pm
hoth
Hoth Therapeutics Announces $2.0 Million Registered Direct Offering [TheStreet.com]
Medium
Report
Hoth Therapeutics Announces $2.0 Million Registered Direct Offering [TheStreet.com]
4/1
01:52 pm
hoth
Hoth Therapeutics Announces $2.0 Million Registered Direct Offering
High
Report
Hoth Therapeutics Announces $2.0 Million Registered Direct Offering
4/1
08:40 am
hoth
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA =1 by Week Six [Yahoo! Finance]
High
Report
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA =1 by Week Six [Yahoo! Finance]
4/1
08:30 am
hoth
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA =1 by Week Six [TheStreet.com]
High
Report
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA =1 by Week Six [TheStreet.com]
4/1
08:14 am
hoth
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA =1 by Week Six
High
Report
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA =1 by Week Six
3/31
08:39 am
hoth
Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology [Yahoo! Finance]
Medium
Report
Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology [Yahoo! Finance]
3/31
08:17 am
hoth
Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology [TheStreet.com]
Medium
Report
Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology [TheStreet.com]
3/31
08:07 am
hoth
Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology
Medium
Report
Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology
3/26
08:30 am
hoth
Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery
High
Report
Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery
3/25
11:17 am
hoth
Hoth Therapeutics (HOTH) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $5.00 price target on the stock.
Low
Report
Hoth Therapeutics (HOTH) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $5.00 price target on the stock.
3/24
08:39 am
hoth
Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption [Yahoo! Finance]
Low
Report
Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption [Yahoo! Finance]
3/24
08:29 am
hoth
Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption [TheStreet.com]
Low
Report
Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption [TheStreet.com]
3/24
08:13 am
hoth
Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption
Medium
Report
Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption
3/10
08:39 am
hoth
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model [Yahoo! Finance]
Low
Report
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model [Yahoo! Finance]
3/10
08:13 am
hoth
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model
Low
Report
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model
3/4
02:49 pm
hoth
Hoth Therapeutics (HOTH) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $5.00 price target on the stock.
Neutral
Report
Hoth Therapeutics (HOTH) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $5.00 price target on the stock.
3/4
08:49 am
hoth
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program [Yahoo! Finance]
Medium
Report
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program [Yahoo! Finance]
3/4
08:31 am
hoth
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program
Neutral
Report
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program
2/24
04:15 pm
hoth
HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES
Medium
Report
HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES